Novo attempts to parry Sanders' GLP-1 pricing complaints by calling out pharma middlemen

Novo Nordisk is standing its ground after the Senate’s Health, Education, Labor and Pensions (HELP) committee recently accused the drugmaker of threatening to bankrupt the U.S. healthcare system with its pricey GLP-1 medicines.